Abstract
The ideal approach to the management of cardiac rhythm disorders depends on the following:
-
1.
Proper identification of the arrhythmia.
-
2.
An understanding of the natural history of the arrhythmia in a particular patient.
-
3.
An understanding of the multiple factors that may precipitate and maintain a cardiac rhythm disturbance in a particular patient.
-
4.
An understanding of the pharmacology of the numerous antiarrhythmic drugs available.
-
5
An appropriate clinical assessment of the risk to the patient due to the cardiac arrhythmia versus the side effects that might ensue upon initiation of treatment with an antiarrhythmic drug.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dreifus LS, Ogawa S: Quality of the ideal anti-arrhythmic drug. Am J Cardiol 39: 466–468, 1977.
Zipes DP: Management of cardiac arrhythmias. In Heart disease. A textbook of cardiovascular medicine, 2nd ed, Braunwald E, (ed), Philadelphia, WB Saunders, 1984, pp 648–682.
Woosley RL, Shand DG: Pharmacokinetics of antiarrhythmic drugs. Am J Cardiol 41: 986–995, 1978.
Bigger JT: Management of arrhythmias. In Heart disease. A textbook of cardiovascular medicine. Braunwald E (ed), Philadelphia, WB Saunders, 1980, pp 691–743.
Giardina E-GV, Heissenbuttel RH, Bigger JT: Intermittent intravenous procaineamide to treat ventricular arrhythmias. Ann Intern Med 78: 183–193, 1973.
Zipes DP, Troup PF: New antiarrhythmic agents: amiodarone, aprindine, disopyramide, ethmozin, mexiletine, tocainide, verapamil. Am J Cardiol 41: 1005–1024, 1978.
Singh BN, Collett JT, Chew CY: New perspectives in the pharmacologic therapy of cardiac arrhythmias. Progr Cardiovasc Dis 22: 243–301, 1980.
Anderson JL, Harrison DC, Meffin PJ, Winkle RA: Antiarrhythmic drugs: Clinical pharmacology and therapeutic uses. Drugs 15: 271–309, 1978.
Velebit V, Podrid P, Lown B, Cohen BH, Graboys TB: Aggravation and provocation of ventricular arrhythmias by antiarrhythmic drugs. Circulation 65: 886–894, 1982.
Frishman WH: β-Adrenoceptor antagonists. New drugs and new indications. N Engl J Med 305:500, 1981.
Frishman WH: The beta-adrenoceptor blocking drugs. Int J Cardiol 2: 165–178, 1982.
Koch-Weser J: Metoprolol. N Engl J Med 301:698, 1979.
Frishman W: Clinical pharmacology of the new 1-adrenergic blocking drugs. Part 1. Pharmaco-kinetic and pharmacodynamic properties. Am Heart J 97:663, 1979.
Connolly ME, Kersting F, Dollery CT: The clinical pharmacology of β-adrenoeeptor blocking drugs. Progr Cardiovasc Dis 19:203, 1976.
Frishman W, Halprin S: Clinical pharmacology of the new β-adrenergic blocking drugs. Part 7. New horizons in β-adrenoeeptor blocking therapy: labetalol. Am Heart J 98:660, 1979.
McDevitt DG: Drug interactions involving β-adrenoceptor blocking drugs. In Cardiovascular and respiratory disease therapy Petri JC, (ed), Amsterdam, Elsevier/North Holland, 1980, pp 21–41.
Smith TW, Amman EM, Friedman PL, Blatt CM, Marsh JD: Digitalis glycosides: Mechanisms and manifestations of toxicity. Progr Cardiovasc Dis 26:413, 1984.
Hoffman BF, Bigger JT: Digitalis and allied cardiac glycosides. The pharmacological basis of therapeutics, 6th ed, Gilman AG, Goodman LS, Gilman A (eds), New York, MacMillan 1980, pp 729–760
Smith TW, Braunwald E: The management of heart failure. In Heart disease. A textbook of cardiovascular medicine, Braunwald E (ed), Philadelphia, WB Saunders, 1980, pp 509–570.
Greenblatt DJ, Duhme DW, Koch-Weser J: Pain and CPK elevation after intramuscular digoxin. N Engl J Med 288:689, 1973.
Cogan JJ, Humphreys MH, Carlson CJ, et al: Acute vasodilator therapy increases renal clearance of digoxin in patients with congestive heart failure. Circulation 64: 973–976, 1981.
Lindenbaum J, Rund DG, Butler VP, et al: Inactivation of digoxin by the gut flora: Reversal by antibiotic therapy. N Engl J Med 305: 789–794, 1981.
Bigger JT: The quinidine-digoxin interaction. Int J Cardiol 1: 109–116, 1981.
Goldfinger SE: Dissimilarities of digoxin. N Engl J Med 285: 1376–1377, 1971.
Smith TW, Haber E, Yeatman L, et al: Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 294: 797–800, 1976.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1986 Martinus Nijhoff Publishing, Boston.
About this chapter
Cite this chapter
Antman, E.M., Rutherford, J.D. (1986). Pharmacological Therapy of Cardiac Arrhythmias: Antiarrhythmic Agents, Beta Adrenoceptor Blocking Agents, and Digitalis Glycosides. In: Coronary Care Medicine. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-2303-7_6
Download citation
DOI: https://doi.org/10.1007/978-1-4613-2303-7_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-9418-4
Online ISBN: 978-1-4613-2303-7
eBook Packages: Springer Book Archive